Barclays raised the firm’s price target on Ultragenyx to $83 from $81 and keeps an Overweight rating on the shares. The firm said that “positive” Phase 3 in GSDIa is “likely approvable,” althorugh the magnitude of corn starch intake reduction appeared smaller than Phase 1/2, which could be partially due to more cautious physician action in a blinded study. Barclays expects further improvement to approach roughly 70% reduction.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- Ultragenyx price target lowered to $109 from $111 at Canaccord
- Ultragenyx price target lowered to $47 from $48 at Wedbush